Molecure S.A. (WSE:MOC)

Poland flag Poland · Delayed Price · Currency is PLN
5.83
-0.06 (-1.02%)
Apr 28, 2026, 5:00 PM CET
-31.81%
Market Cap 120.12M
Revenue (ttm) 6.52M
Net Income (ttm) -15.69M
Shares Out 20.60M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,825
Average Volume 80,681
Open 5.89
Previous Close 5.89
Day's Range 5.69 - 5.94
52-Week Range 4.98 - 9.06
Beta 1.08
RSI 56.72
Earnings Date May 18, 2026

About Molecure

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-4... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 71
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MOC
Full Company Profile

Financial Performance

In 2025, Molecure's revenue was 6.52 million, an increase of 123.34% compared to the previous year's 2.92 million. Losses were -15.69 million, -49.86% less than in 2024.

Financial Statements

News

There is no news available yet.